Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Albany Molecular Research Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Albany Molecular Research Inc, Medical Devices Deals, 2011 to YTD 2017 11
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deal Details 15
Private Equity 15
Carlyle Group and GTCR Acquires Albany Molecular Research 15
Mandarin Capital Management Completes Sale Of 30% Stake In Euticals 17
Mandarin Capital Partners And Euticals Acquires 35% Stake In Suzhou Tianma Pharma Group Tianji Bio-Pharma 18
Partnerships 19
Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 19
Albany Molecular Research Enters into Agreement with University at Albany 20
Nemus Bioscience Enters into Agreement with Albany Molecular Research 21
Albany Molecular Research Enters into Agreement with New York Center for Nanomedicine Research 22
Eagle Pharma Enters into Co-Development Agreement with Albany Molecular Research 23
Albany Molecular Research Enters into Agreement with Icagen 24
Albany Molecular Research Enters into Co-Marketng Agreement with Multispan 25
Albany Molecular Research Enters into Agreement with Saneca Pharma 26
Albany Molecular Research Enters into Agreement with PerkinElmer 27
Albany Molecular Research Enters into Agreement with HarkerBIO 28
Albany Molecular Research Enters Into Smartsourcing Partnership With Codexis 29
Albany Molecular Enters Into An Agreement With Knopp Biosciences For Discovery Services 30
AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 31
Creative Antibiotics Enters Into Co-Development Agreement With Albany Molecular Research 32
Proteros biostructures Enters Into An Agreement With Albany Molecular Research 33
Licensing Agreements 34
Denovo Biopharma Enters into Licensing Agreement with Albany Molecular Research 34
Albany Molecular Research Enters into Licensing Agreement with Broad Institute 35
Albany Molecular Research Enters into Licensing Agreement with Teewinot Life Sciences 36
Chai Therapeutics Exercises Option For Licensing Agreement With Albany Molecular Research To Develop ALB 109564(a) 37
AMRI Enters Into Licensing Agreement With Genentech 38
Equity Offering 39
Albany Molecular Research Plans to Raise Funds in Public Offering 39
Albany Molecular Research to Raise Funds through Private Placement of Shares 40
Albany Molecular Research Files Registration Statement For Public Offering Of Securities For US$50 Million 41
Debt Offering 42
Albany Molecular Research Completes Private Placement Of Notes Due 2018 For US$130 Million 42
Acquisition 44
Albany Molecular Research Acquires Euticals 44
Albany Molecular Research Acquires Gadea Grupo Farmaceutico 46
Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 47
Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 48
Albany Molecular Research Completes Acquisition of OSO BioPharma for USD110 Million 49
Emami Plans to Acquire 33% Stake in AMRI form Bengal Shrachi Housing Development 50
Albany Molecular Research Acquires Cedarburg Pharmaceuticals 51
Clave Mayor Sells 9.73% Stake In Gadea Grupo Farmaceutico 53
Euticals Acquires Archimica, Fine Chemical Company, From TowerBrook Capital Partners 54
Euticals Acquires 30% Stake in Tianma Tianji Pharma 55
Albany Molecular Research Inc – Key Competitors 56
Albany Molecular Research Inc – Key Employees 57
Albany Molecular Research Inc – Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Recent Developments 60
Financial Announcements 60
May 09, 2017: AMRI Announces First Quarter 2017 Results 60
Feb 21, 2017: AMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 Outlook 61
Nov 08, 2016: AMRI ANNOUNCES THIRD QUARTER 2016 RESULTS 64
Aug 04, 2016: AMRI Announces Second Quarter 2016 Results 67
May 10, 2016: AMRI Announces First Quarter 2016 Results 70
Feb 17, 2016: AMRI Announces Fourth Quarter and Full Year 2015 Results and Provides 2016 Outlook 72
Corporate Communications 75
Oct 30, 2017: AMRI Appoints Paul Feuerman as Senior Vice President, General Counsel and Head of Business Development 75
Oct 02, 2017: AMRI Names Joseph D. Sangregorio as Senior Vice President and Chief Human Resources Officer 76
Sep 12, 2017: AMRI Names Stephen Leonard as Senior Vice President Head of Global Operations 77
Feb 17, 2016: AMRI Appoints David H. Deming and Kenneth P. Hagen to Board of Directors 78
Feb 04, 2016: AMRI Appoints Anthony J. Maddaluna to Board of Directors 79
Legal and Regulatory 80
Sep 12, 2017: 3ST Research Files Litigation Alleging Fraud and Conversion of Inventors Intellectual Property Rights by Albany Molecular Research (AMRI) 80
Government and Public Interest 81
Jul 27, 2016: UB CAT awards over $500K to innovative life sciences companies 81
Product News 82
Oct 18, 2017: AMRI’s SSCI Adds Cobalt Light Systems Transmission Raman Spectrometer to Expand Vibrational Spectroscopy Services 82
Other Significant Developments 83
Nov 30, 2017: AMRI Doubles Bulk API Aseptic Manufacturing Capacity 83
Oct 12, 2017: AMRI Launches Stand-Alone Service; Expanding Solutions for Impurity Analysis and Toxicology Risk Assessment 84
Aug 29, 2016: Albany Molecular Research announces restructuring plan of certain operations in U.S.and Europe 85
Jun 14, 2016: AMRI Selected as a Dedicated Chemical Biology Consortium Center to Expand Drug Development 86
Appendix 87
Methodology 87
About GlobalData 87
Contact Us 87
Disclaimer 87
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Albany Molecular Research Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Albany Molecular Research Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Albany Molecular Research Inc, Medical Devices Deals, 2011 to YTD 2017 11
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Carlyle Group and GTCR Acquires Albany Molecular Research 15
Mandarin Capital Management Completes Sale Of 30% Stake In Euticals 17
Mandarin Capital Partners And Euticals Acquires 35% Stake In Suzhou Tianma Pharma Group Tianji Bio-Pharma 18
Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 19
Albany Molecular Research Enters into Agreement with University at Albany 20
Nemus Bioscience Enters into Agreement with Albany Molecular Research 21
Albany Molecular Research Enters into Agreement with New York Center for Nanomedicine Research 22
Eagle Pharma Enters into Co-Development Agreement with Albany Molecular Research 23
Albany Molecular Research Enters into Agreement with Icagen 24
Albany Molecular Research Enters into Co-Marketng Agreement with Multispan 25
Albany Molecular Research Enters into Agreement with Saneca Pharma 26
Albany Molecular Research Enters into Agreement with PerkinElmer 27
Albany Molecular Research Enters into Agreement with HarkerBIO 28
Albany Molecular Research Enters Into Smartsourcing Partnership With Codexis 29
Albany Molecular Enters Into An Agreement With Knopp Biosciences For Discovery Services 30
AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 31
Creative Antibiotics Enters Into Co-Development Agreement With Albany Molecular Research 32
Proteros biostructures Enters Into An Agreement With Albany Molecular Research 33
Denovo Biopharma Enters into Licensing Agreement with Albany Molecular Research 34
Albany Molecular Research Enters into Licensing Agreement with Broad Institute 35
Albany Molecular Research Enters into Licensing Agreement with Teewinot Life Sciences 36
Chai Therapeutics Exercises Option For Licensing Agreement With Albany Molecular Research To Develop ALB 109564(a) 37
AMRI Enters Into Licensing Agreement With Genentech 38
Albany Molecular Research Plans to Raise Funds in Public Offering 39
Albany Molecular Research to Raise Funds through Private Placement of Shares 40
Albany Molecular Research Files Registration Statement For Public Offering Of Securities For US$50 Million 41
Albany Molecular Research Completes Private Placement Of Notes Due 2018 For US$130 Million 42
Albany Molecular Research Acquires Euticals 44
Albany Molecular Research Acquires Gadea Grupo Farmaceutico 46
Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 47
Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 48
Albany Molecular Research Completes Acquisition of OSO BioPharma for USD110 Million 49
Emami Plans to Acquire 33% Stake in AMRI form Bengal Shrachi Housing Development 50
Albany Molecular Research Acquires Cedarburg Pharmaceuticals 51
Clave Mayor Sells 9.73% Stake In Gadea Grupo Farmaceutico 53
Euticals Acquires Archimica, Fine Chemical Company, From TowerBrook Capital Partners 54
Euticals Acquires 30% Stake in Tianma Tianji Pharma 55
Albany Molecular Research Inc, Key Competitors 56
Albany Molecular Research Inc, Key Employees 57
Albany Molecular Research Inc, Subsidiaries 58